«In all the subgroups we tested the longer arm tended to be better than the shorter one, but we did detect an interaction between
docetaxel dose and disease - free survival,» Joensuu said.
Not exact matches
According to Joensuu, this suggested that the
dose of
docetaxel administered with trastuzumab may influence survival outcomes.
Researchers are also trying to learn about: - The level of MM - 121 that remains in the human body at different time points when MM - 121 is combined with
docetaxel or pemetrexed - The relationship between the biomarker, heregulin, and cancer cell growth (disease progression) in people
dosed only with
docetaxel or pemetrexed.
The U.S. drug maker released a statement on Monday saying that its Keynote - 010 study, a randomized Phase two - third trial, showed that patients who were taking two different
doses of Keytruda (FDA - approved two mg / kg
dose and treatment
dose of 10 mg / kg given every three weeks) had longer survival compared to those who took
docetaxel, the drug widely used for non-small cell lung cancer (NSCLC).
There was one treatment - related death in the erlotinib group, and 22.1 % of
docetaxel patients and 29.0 % of erlotinib patients suffered adverse events that led to
dose modification.